Methylphenidate in Myotonic Dystrophy Type 1
Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1M2S8
- Institute of Readaptation in Physical Deficiency
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adults
- Epworth score ≥ 10
- Diagnosis of myotonic dystrophy type 1
Exclusion Criteria:
- hypersensibility to methylphenidate
- Pregnancy
- Patients who receive drugs that interfere with methylphenidate
- Cognitive impairment
- Sleep apnea
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Arm 1: Methylphenidate versus baseline
|
One Tablet of methylphenidate, 20 mg per day during 3 weeks
Other Names:
|
|
Placebo Comparator: Arm 2: Placebo versus baseline
One table placebo per day during 3 week
|
one tablet placebo per day during 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline of excessive daytime sleepiness
Time Frame: 3 weeks after treatment
|
3 weeks after treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline of POMS, Rand36-Item Health survey and mean sleep latency
Time Frame: 3 weeks after treatment
|
Mean sleep latency was measured using the behavioural Osler's test
|
3 weeks after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jack J Puymirat, MD, University Laval
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Muscular Disorders, Atrophic
- Heredodegenerative Disorders, Nervous System
- Muscular Dystrophies
- Myotonic Disorders
- Myotonic Dystrophy
- Disorders of Excessive Somnolence
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Methylphenidate
Other Study ID Numbers
Other Study ID Numbers
- AFM-12117 (Other Grant/Funding Number: AFM-12117)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.